ORAGENICS, INC. Stock or Unit Option Plan Expense
ORAGENICS, INC. (OGEN) reported Stock or Unit Option Plan Expense of $310.42 thousand for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2019-08-14
- ORAGENICS, INC. stock or unit option plan expense for the quarter ending 2019-06-30 was $164.59K, a 100.75% increase year-over-year.
- ORAGENICS, INC. stock or unit option plan expense for the quarter ending 2019-03-31 was $145.83K, a 23.25% increase year-over-year.
- ORAGENICS, INC. stock or unit option plan expense for the quarter ending 2018-12-31 was $147.43K, a 13.71% increase year-over-year.
- ORAGENICS, INC. stock or unit option plan expense for the quarter ending 2018-09-30 was $648.30K, a 507.64% increase year-over-year.
- ORAGENICS, INC. stock or unit option plan expense for fiscal 2018 was $996.04K, a 127.78% increase from fiscal 2017.
- ORAGENICS, INC. stock or unit option plan expense for fiscal 2017 was $437.28K, a 10.25% decline from fiscal 2016.
- ORAGENICS, INC. stock or unit option plan expense for fiscal 2016 was $487.22K, a 36.78% decline from fiscal 2015.
- ORAGENICS, INC. stock or unit option plan expense for fiscal 2015 was $770.70K, a 317.65% increase from fiscal 2014.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month |
|---|---|---|---|---|
| 2019-06-30 | $164.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $310.42K 10-Q · filed 2019-08-14 | $457.84K derived: sum of 3 quarters · filed 2019-08-14 | $1.11M derived: sum of 4 quarters · filed 2019-08-14 |
| 2019-03-31 | $145.83K 10-Q · filed 2019-05-13 | $293.25K derived: sum of 2 quarters · filed 2019-05-13 | $941.56K derived: sum of 3 quarters · filed 2019-05-13 | $1.02M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-12-31 | $147.43K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $795.73K derived: sum of 2 quarters · filed 2019-03-29 | $877.71K derived: sum of 3 quarters · filed 2019-08-14 | $996.04K 10-K · filed 2019-03-29 |
| 2018-09-30 | $648.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $730.29K derived: sum of 2 quarters · filed 2019-08-14 | $848.61K 10-Q · filed 2018-11-13 | $978.26K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-06-30 | $81.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $200.31K 10-Q · filed 2019-08-14 | $329.96K derived: sum of 3 quarters · filed 2019-08-14 | $436.65K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $118.32K 10-Q · filed 2019-05-13 | $247.97K derived: sum of 2 quarters · filed 2019-05-13 | $354.66K derived: sum of 3 quarters · filed 2019-05-13 | $437.10K derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-12-31 | $129.65K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $236.34K derived: sum of 2 quarters · filed 2019-03-29 | $318.78K derived: sum of 3 quarters · filed 2019-03-29 | $437.28K 10-K · filed 2019-03-29 |
| 2017-09-30 | $106.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $189.13K derived: sum of 2 quarters · filed 2018-11-13 | $307.63K 10-Q · filed 2018-11-13 | $409.86K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | $82.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $200.94K 10-Q · filed 2018-08-13 | $303.16K derived: sum of 3 quarters · filed 2018-08-13 | $528.59K derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | $118.50K 10-Q · filed 2018-05-15 | $220.73K derived: sum of 2 quarters · filed 2018-05-15 | $446.15K derived: sum of 3 quarters · filed 2018-05-15 | $441.96K derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $102.23K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $327.65K derived: sum of 2 quarters · filed 2018-02-16 | $323.46K derived: sum of 3 quarters · filed 2018-02-16 | $487.22K 10-K · filed 2018-02-16 |
| 2016-09-30 | $225.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $221.23K derived: sum of 2 quarters · filed 2017-10-31 | $384.99K 10-Q · filed 2017-10-31 | |
| 2016-06-30 | -$4.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $159.57K 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $163.76K 10-Q · filed 2017-05-15 | |||
| 2015-12-31 | $770.70K 10-K · filed 2017-02-27 | |||
| 2014-12-31 | -$3.80K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $184.53K 10-K · filed 2015-02-27 | ||
| 2014-09-30 | $188.33K 10-Q · filed 2014-11-03 | |||
| 2013-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $3.45M 10-K · filed 2015-02-27 | ||
| 2013-09-30 | $1.62M 10-Q · filed 2014-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |